Navigation Links
Breast-Specific Gamma Imaging Proves Highly Sensitive for the Detection of Ductal Carcinoma In Situ

CHICAGO, Nov. 30 /PRNewswire/ -- Breast-Specific Gamma Imaging (BSGI) has been proven to be a highly sensitive imaging technique for the detection of ductal carcinoma in situ (DCIS), a difficult to diagnose breast cancer. BSGI is a molecular breast imaging technique that can see lesions independent of tissue density and discover very early stage cancers. According to findings presented today at the annual meeting of the Radiological Society of North America (RSNA), BSGI is an effective adjunct imaging modality for the detection of DCIS with an overall sensitivity of 89.5 percent.

In the retrospective study, 55 women with 57 biopsy-proven DCIS lesions were included. Patients had BSGI with the Dilon 6800 Gamma Camera with standard mammographic views. Image findings were compared to findings at biopsy or surgical excision. The sensitivity for the detection of DCIS were calculated and correlated with pathologic size of the DCIS.

Of the 38 cases of biopsy-proven DCIS in 34 women, 89.5 percent were detected with BSGI. The findings indicate that the pathologic tumor size of the DCIS ranged from 0.1-3.1 centimeters in 33 cases. BSGI had sensitivity for 1 centimeter or small DCIS of 90.5 percent and can detect DCIS as small as 1 millimeter.

"The sensitivity of BSGI detection of DCIS is comparable to that reported for MRI detection of DCIS (87.9 percent and 92 percent). However, BSGI is more cost-effective than MRI, can be performed in all patients regardless of claustrophia, renal insufficiency, metal/cardiac implants or patient weight," said Dr. Rachel Brem, Director of Breast Imaging and Intervention at George Washington University Medical Center in Washington, D.C., and Vice Chair of the Department of Radiology.

The BSGI for the study was conducted at The George Washington University Medical Center in Washington, DC using a Dilon 6800 Gamma Camera, a high-resolution, small field-of-view gamma camera, optimized to perform BSGI. With BSGI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than the normal surrounding tissue and generally appear as "hot spots" on the BSGI image.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a high-resolution, compact gamma camera, optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit

SOURCE Dilon Diagnostics

SOURCE Dilon Diagnostics
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy
2. Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI)
3. Breast-Specific Gamma Imaging Proves Cost-Effective for Pre-Surgical Planning of Patients with Known Cancer Diagnosis
4. Community Breast Center Experience Shows Real-World Application of Breast-Specific Gamma Imaging Has Significant Impact on Clinical Care
5. Bertrand Study Finds Significant Value in Breast-Specific Gamma Imaging (BSGI) as an Adjunctive Procedure in Breast Diagnostics
6. Saint Josephs Hospital First in Georgia to Offer Noninvasive Treatment of Brain Disorders with Leksell Gamma Knife Perfexion
7. Schering-Plough Announces European Launch of BRIDION(R) (Sugammadex)
8. U.S. FDA Issues Action Letter for Sugammadex
9. BRIDION(R) (sugammadex) Injection - First and Only Selective Relaxant Binding Agent - Approved in European Union
10. European Unions CHMP Issues Positive Opinion on Sugammadex
11. Study Results of GAMMAGARD S/D and GAMMAGARD LIQUID in Patients with Mild-to-Moderate Alzheimers Disease Announced
Post Your Comments:
(Date:11/25/2015)... -- On Tuesday, November 24, 2015, the jury ... Medical Technology, Inc. for product liability and misrepresentation ... device, awarded $11 million in favor of Plaintiff ... three days of deliberations, the jury found that ... and unreasonably dangerous, and that Wright Medical made ...
(Date:11/25/2015)... SAN DIEGO , Nov. 25, 2015  Trovagene, ... molecular diagnostics, today announced that Chief Executive Officer Antonius ... at the 27 th Annual Piper Jaffray Healthcare ... Conference at the New York Palace Hotel in ... 2015 at 1:30 p.m. EST. Mr. Schuh will be ...
(Date:11/25/2015)... 25, 2015 --> ... glucose devices was valued at $11,171.1 million in 2014, ... of 5.7% during 2015 - 2022. The global market ... prevalence of diabetes. In addition, the increase in obese ... contributing to the growth of the market. Furthermore, technological ...
Breaking Medicine Technology:
(Date:11/25/2015)... , ... November 25, 2015 , ... ... for all, Water For Empowerment ™ attracts volunteers together who want to ... by empowering women as key stakeholders in the process. The non-profit launched its ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
(Date:11/25/2015)... ... November 26, 2015 , ... ... (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public R&D ... Nairobi (UNON) for the opening of the 5th African Network for Drugs and ...
(Date:11/25/2015)... Los Angeles, CA (PRWEB) , ... November 25, 2015 , ... ... advanced da Vinci surgical robot is being more and more widely heralded as a ... robotic assisted da Vinci method has over traditional laparoscopic surgery is that it can ...
(Date:11/25/2015)... ... 2015 , ... On November 25, 2015, officials of Narconon Arrowhead , ... release of a new cutting edge recovery program that has been 50 years in ... and alcohol-addicted individuals with the purpose to free addicts from the symptoms and negative ...
Breaking Medicine News(10 mins):